postpartum%20hemorrhage
POSTPARTUM HEMORRHAGE
Postpartum hemorrhage is defined as blood loss of ≥500 mL for vaginal delivery after completion of the 3rd stage of labor while for cesarean delivery, the cut-off is 1000 mL.
It may present as either early (primary) or late (secondary) postpartum hemorrhage.
Postpartum hemorrhage may produce hemodynamic instability during the 1st 24 hours after delivery.
Drug Information

Indication: Obstet Induce parturition in cases of uterine inertia during the 3rd stage of labour. Prophylactically & t...

Indication: Hemorrhagic diseases & abnormal bleeding. Allergic & inflammatory symptoms.

Indication: Abortion between the 13th & 20th wk of gestation & in the following conditions related to 2nd trimeste...

Indication: Induction of labour for medical reasons (eg, postmaturity, pre-mature rupture of the membranes, preeclampsia)....

Indication: Haemorrhage or threatened haemorrhage associated w/ excessive fibrinolysis. Management of haemophiliacs underg...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 27 Dec 2018
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
23 Dec 2018
TX-001HR, a fixed-dose combination of oestradiol and progesterone, yields clinically meaningful improvements in the frequency and/or severity vasomotor symptoms in menopausal women with a uterus, according to a study.
22 Dec 2018
Breastfeeding for more than 6 months after birth appears to be independently associated with a long-term decrease in waist circumference, reports a recent study.
Elaine Soliven, 11 Jul 2018

Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.